Researchers from the University of Michigan in Ann Arbor and North CarolinaStateUniversity at Raleigh found primary bile acids in the small intestine allowed harmful bacteria to grow regardless of antibiotic treatments. But when those same spores reached the large intestine, home to secondary bile acids, the bacteria were stopped in their tracks. After antibiotic treatment, which eliminated the intestinal bacteria that bolster secondary acids, C. diff was able to grow quickly.
“[T]argeting growth of C. diff will prove most important for future therapeutics and that antibiotic-related changes are organ specific,” the authors conclude. “Understanding how the gut microbiota regulates bile acids throughout the intestine will aid the development of future therapies for C. diff infection and other metabolically relevant disorders such as obesity and diabetes.”
More articles on infection control:
Gene rendering superbugs resistant to antibiotics found in Canada
CMS launches 3-year pilot project to improve infection control assessment for hospitals
FDA moves to halt shipping from device manufacturer linked to patient deaths
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
